A5038654843- Cutaneous lymphoproliferative disorders research
- CAR-T cell therapy research
- Psoriasis: Treatment and Pathogenesis
- Autoimmune Bullous Skin Diseases
- Dermatology and Skin Diseases
- Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Melanoma and MAPK Pathways
- Fungal Infections and Studies
- Nonmelanoma Skin Cancer Studies
- Nail Diseases and Treatments
- Cancer and Skin Lesions
- Brain Metastases and Treatment
- Tumors and Oncological Cases
- Eosinophilic Disorders and Syndromes
- Monoclonal and Polyclonal Antibodies Research
- Autoimmune and Inflammatory Disorders
- Urticaria and Related Conditions
- Immunotherapy and Immune Responses
- Cutaneous Melanoma Detection and Management
- Glioma Diagnosis and Treatment
- Drug-Induced Hepatotoxicity and Protection
- Reconstructive Facial Surgery Techniques
- Spondyloarthritis Studies and Treatments
Aix-Marseille Université
2016-2025
Assistance Publique Hôpitaux de Marseille
2018-2024
Lymphoma Study Association
2024
University of Pittsburgh Medical Center
2024
UPMC Hillman Cancer Center
2024
Hôpital Nord
2014-2023
University Dermatology
2023
Centre de Recherche en Cancérologie de Marseille
2018-2022
Inserm
2018-2022
Hôpital de la Timone
2013-2021
Abstract These guidelines were developed by the psoriasis research group of French Society Dermatology with aim providing updated decision‐making algorithms for systemic treatment adult patients moderate‐to‐severe psoriasis. Our generated after rigorous evaluation existing on and publications concerning new treatments, not yet incorporated into guidelines. A total nine 53 related to treatments found meet our criteria use in generation algorithms. We have proposed two assess therapeutic...
Background Primary cutaneous lymphomas (PCLs) are a heterogeneous group of T-cell (CTCL) and B-cell (CBCL) malignancies. Little is known about their epidemiology at initial presentation in Europe potential changes over time. Objectives The aim this retrospective study was to analyse the frequency PCLs French Cutaneous Lymphoma Registry (GFELC) describe demography patients. Methods Patients with centrally validated diagnosis primary PCL, diagnosed between 2005 2019, were included. Results...
Sézary syndrome is an extremely rare and fatal cutaneous T-cell lymphoma (CTCL). Mogamulizumab, anti-CCR4 monoclonal antibody, has recently been associated with increased progression-free survival in a randomized clinical trial CTCL. We aimed to evaluate OS prognostic factors syndrome, including treatment mogamulizumab, real-life setting.
Intratumoral TLR9 agonists and anti-PD-1 produce clinical responses broad immune activation. We conducted a single-arm study of neoadjuvant agonist vidutolimod combined with nivolumab in high-risk resectable melanoma. In 31 evaluable patients, 55% major pathologic response (MPR) was observed, meeting primary endpoint. MPR associated necrosis, melanophagocytosis increased CD8
The treatment of advanced-stage cutaneous T-cell lymphoma (CTCL) remains an unmet medical need. Mogamulizumab, anti-KIR3DL2, and brentuximab vedotin (BV), anti-CD30 antibody-drug conjugate (ADC) coupled with monomethyl-auristatin-E (MMAE), provided encouraging results, but new targeted therapies are needed. Inducible costimulator (ICOS), a costimulatory receptor, is promising therapeutic target, not only because it expressed by malignant T cells in CTCL also its connection the suppressive...
9591 Background: Cutaneous squamous cell carcinoma (cSCC) is the second commonest cutaneous malignancy, accounting for 20% of malignancies and 75% non-melanoma skin cancer deaths. Anti-PD-1 approved in unresectable metastatic cSCC, associated with high rates pathologic response resectable locally advanced (LA) cSCC. We conducted a phase II single-arm neoadjuvant trial pembrolizumab (P) patients PD-1 naïve LA Methods: Patients AJCC/UICC ≥T3 (or T2 ≥2 BWH high-risk features) and/or N+ disease...
New highly effective drugs for moderate-to-severe cutaneous psoriasis are regularly marketed, and the hierarchy of treatments thus requires frequent review.
Abstract Background Few epidemiologic data are available regarding biologic liver abnormalities during psoriasis flares. Objectives The aim of this study was to assess the prevalence biological test (LTA) in a population and risk factors associated with LTA. Methods A retrospective cross‐sectional four hospital dermatology tertiary care centres included patients admitted for severe flare between 1st January 2010 31st December 2011. During same period, control selected comprising contact...
Abstract Background: In lung adenocarcinoma, molecular profiling of actionable genes has become essential to set up targeted therapies. However, the feasibility and relevance from cerebrospinal fluid (CSF) in context meningeal metastasis have been poorly assessed. Methods: We selected patients with stage IV adenocarcinoma harbouring metastatic cells CSF after cytological analysis. Seven samples six were eligible for testing epidermal growth factor receptor ( EGFR ), V-Ki-ras2 Kirsten rat...
Background: Our objective was to describe the clinical, histological characteristics, and disease outcome of a cohort mycosis fungoides (MF) diagnosed during childhood including status at adulthood. Methods: This is retrospective multicentre survey patients aged under 18 years diagnosis with histologically confirmed MF. Patients’ clinical treatments, (for followed for more than 12 months) were analysed. Results: Forty-six included (median age diagnosis: 11 years; M:F sex ratio: 3:1) 39 (85%)...
Click here for the corresponding questions to this CME article.
To the Editor: Cutaneous involvement by acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) is very uncommon. Current knowledge of this situation remains limited, based on small retrospective case series without data regarding overall survival (OS) and associated prognostic factors nor molecular features.1-3 Besides, no about differential antigen expression tumoral cells in skin vs bone marrow are available.
Our case series reports a new immune-related adverse event and highlights three important facts. Firstly, granulomatous reactions not only occur in the skin, but can also affect bones. Secondly, although possibly transient spontaneously regressive, such lesions may result protracted functional disabilities owing to their location interest of systemic steroids this setting remains be established. Finally, they should mistaken with an unfavourable evolution underlying disease seem instead...
TNF weakly inducer of apoptosis (TWEAK) is member the ligand superfamily. Various data support that TWEAK produced by synovial macrophages may contribute to synovitis observed in psoriatic arthritis (PsoA). In PsoA, anti-TNF therapy has been successful agreement with key role pathogenesis and generation PsoA patients autoantibodies referred as "beneficial autoimmunity pro-inflammatory mediators". However, TNF-alpha regulation modulation inflammation during remains unknown.We have studied...